RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00034916.xml
Nervenheilkunde 2018; 37(11): 835-836
DOI: 10.1055/s-0038-1675716
DOI: 10.1055/s-0038-1675716
Verschiedenes
Kopfschmerz News
Deutsche Migräne- und KopfschmerzgesellschaftWeitere Informationen
Publikationsverlauf
Publikationsdatum:
30. Oktober 2018 (online)
#
-
Literatur
- 1 Cernuda-Morollón E. et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 2013; 81 (14) 1191-1196.
- 2 Cernuda-Morollón E. et al. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine. Headache 2014; 54: 987-95.
- 3 Edvinsson L. et al. CGRP as the target of new migraine therapies – successful translation from bench to clinic. Nature Reviews Neurology 2018; 14 (06) 338.
-
Literatur
- 1 Cernuda-Morollón E. et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 2013; 81 (14) 1191-1196.
- 2 Cernuda-Morollón E. et al. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine. Headache 2014; 54: 987-95.
- 3 Edvinsson L. et al. CGRP as the target of new migraine therapies – successful translation from bench to clinic. Nature Reviews Neurology 2018; 14 (06) 338.